I have identified some genes that are linked with cancer. Some of these genes have already been studied for their expression in cancer, but the variants have never been reported or studied. Is there any possibility for me to publish these causative variants in cancer despite the fact that these genes were already studied for the expression in cancer?
1 answer
Dear,
Yes of course, however this paper would be bit towards clinically oriented. Clinicians usually implement bioinformatics to elucidate new mutations that has not been described. We call this extending/delineating the phenotype. Your paper can mention:
-What bioinformatic technique has been implemented to detect the variants.
-If these variants are detected via WGS/WES, then do they show up as well with the Gold-Standard sanger sequencing.
-What in-vitro/in-vivo functional studies have been conducted to make sure that these variants are behind a patient's phenotype.
-What are the characteristics of the phenotype? Does it make the cancer more aggressive? Does patients carrying this variant show slower prognosis etc.
Regards,
Log in to answer this question.
-
Can non-driver mutations disrupt the function of proteins and further affect a cellular pathway?
written by Zahra •
-
RS numbers and "novelty"
written by Nosey •
-
Variant calling from RNA-seq?
written by zizigolu
-
Microaaray data analysis
written by au.rinki.bio •
-
Non-coding variants in TCGA data
written by MAPK
-
Using cbioportal gene ontology for new gene/variants discovery
written by MAPK
-
How to validate genes identified computationally
written by MAPK
-
COSMIC data and rare variant
written by MAPK
-
What could be the reason for having mutations in too many cancer samples?
written by MAPK
-
Gene prediction tool
written by MAPK
